Post by
Noteable on Oct 12, 2023 9:31am
Tempest Therap. From $0.23 to $9.77 in 1 day
4,247% increase in share price from October 10th to October 11, 2023
Comment by
Noteable on Oct 12, 2023 11:16am
Tempest Phase Ib/II study is being run by Roche, which is responsible for managing the operations of the trial. https://www.biospace.com/article/tempest-s-stock-skyrockets-4-000-percent-on-early-data-for-hepatocellular-carcinoma-/
Comment by
fox7mf on Oct 12, 2023 11:52am
Many of these investors refuse to hold MC accountable for anything. This situation is deplorable and we continue to be kept in the dark. Some here even say share price doesn't matter, lol. GL everyone.
Comment by
fox7mf on Oct 12, 2023 1:42pm
SP matters when management can't create shareholder value. Nobody knows about Oncy because of a deficient sales team. What, are we hoping for a 4000% day now, lol? Defecate in one hand, hope in the other...the posters here who are lashing out at my posts are doing so because they too are frustrated and losing confidence. So be it...good luck all.